Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

612
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
612
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.9K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

536
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
536
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

305
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
305

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Mild cognitive impairment in Parkinson's disease: current view.

Frontiers in cognition·2026
Same author

Psychosis in Huntington disease: a short update.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

The enigma of vascular dementia: current state and emerging perspectives.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Depression and apathy in frontotemporal dementia: a short assessment of facts and outlook.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Is there a link between multiple sclerosis and Alzheimer disease? A critical note.

Journal of neural transmission (Vienna, Austria : 1996)·2025
Same author

Comorbid Pathologies and Their Impact on Dementia with Lewy Bodies-Current View.

International journal of molecular sciences·2025

相关实验视频

Updated: Jul 27, 2025

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

17.4K

多重系统缩 - 一个临床病理学更新.

Kurt A Jellinger1

  • 1Institute of Clinical Neurobiology, Vienna, Austria.

Free neuropathology
|June 7, 2023
PubMed
概括

多重系统缩 (MSA) 是一种致命的神经退行性疾病,其特点是α-synuclein沉积物. 研究正在推进对其复杂病原学的理解,并探索这种无法治愈的疾病的新治疗策略.

科学领域:

  • 神经科学是一个神经科学.
  • 病理学 病理学 病理学
  • 遗传学 遗传学 是一个

背景情况:

  • 多重系统缩 (MSA) 是一种致命的,成人发作的神经退行性疾病,病因不明.
  • 临床上,它呈现出对Levodopa无反应的帕金森症,小脑,运动和自主功能障碍.
  • MSA是一种α-synucleinopathy,涉及多个神经系统区域的glioneuronal退化.

研究的目的:

  • 阐明了多系统性缩 (MSA) 的进展背后的分子机制.
  • 了解涉及α-synuclein (αSyn) 传播和细胞功能障碍的病变.
  • 突出需要多学科研究,以开发有效的治疗方法.

主要方法:

  • 用小鼠模型和人类患者进行的研究,以了解疾病的进展.
  • 对α-synuclein (αSyn) 沉积和细胞间传播的分析.
  • 对包括氧化应激和神经炎症在内的致病机制的当前理解的审查.

主要成果:

  • MSA的发病包括类αSyn传播,氧化应激,蛋白质和线粒体功能障碍以及神经炎症.
  • 疾病的进展导致神经退行,脱髓化和多系统参与.
  • 用生物标志物改善了诊断准确性,尽管严重的痴呆症很少见.
关键词:
动物模型动物模型生物标志物 生物标志物埃蒂奥巴托基尼斯的产生.实验性治疗学是一种实验性疗法.脊髓神经元退化症 脊髓神经元退化症多重系统缩多重系统缩像子一样的播种.α-synuclein 是一种同核蛋白.

更多相关视频

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
08:29

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

14.1K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.5K

相关实验视频

Last Updated: Jul 27, 2025

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

17.4K
Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
08:29

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

14.1K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.5K

结论:

  • 多个系统缩 (MSA) 的发病过程复杂,涉及多个相互作用的分子和细胞通路.
  • 尽管诊断得到了改进,临床试验正在进行中,但仍然缺乏有效的疾病修饰疗法.
  • 迫切需要进行多学科研究,以揭示开发MSA有效治疗方法的遗传和分子基础.